CTVA 241220 55.00P (CTVA241220P55000) Stock Options, News & Quotes

0.05
-0.10-66.67%

15min DelayClose Dec 20 16:00 ET

0.05High0.05Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Movers and Shakers

Apr 12 07:23

Columns Today's Morning Movers and Top Ratings: JPM, C, WFC, GTLB and More

Morning Movers
Gapping up
$Citigroup (C.US)$ shares increased by more than 2% after the bank reported revenue of $21.1 billion, surpassing analysts' expectations.
$Blackrock (BLK.US)$ 's stock grew by 2% following a quarterly report that exceeded expectations, with earnings per share of $9.81 on revenue of $4.73 billion.
$Globe Life (GL.US)$ shares surged approximately 9% in extended trading on Friday, recovering from a more than 50%...

Moomoo AI

Mar 22 09:32

Corteva's rising ROCE and efficient capital use are promising, but growing current liabilities may pose new risks. Despite this, the stock has given a decent 23% return over the past three years, indicating these developments are gaining deserved attention.

Returns Are Gaining Momentum At Corteva (NYSE:CTVA)

Moomoo AI

Mar 4 04:27

Corteva's high P/E ratio is sustained by its projected growth surpassing the broader market. Shareholders are at ease with the P/E, confident in the company's future earnings. The share price isn't anticipated to drop significantly soon under these conditions.

Corteva, Inc. (NYSE:CTVA) Not Lagging Market On Growth Or Pricing

Moomoo AI

Feb 28 06:06

The CEO of Lavie Bio, Amit Noam, expressed satisfaction at achieving this milestone with Corteva, stating that the agreement showcases Lavie Bio's technological capabilities and enables the swift introduction of groundbreaking ag-biological solutions.

Press Release: Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M After Meeting Corteva's Licensing Agreement Requirements

Moomoo AI

Feb 1 16:26

Corteva's guidance dispels concerns of lower earnings due to falling crop prices. Aptiv's 2024 forecast predicts a 7% sales growth despite stagnant global auto production. TD Cowen analyst Gautam Khanna deems Trane's results as 'good enough', rating the stock as Buy with a $235 price target.

Corn, Cars, and Cooling: 3 Earnings Reports That Tell a Story -- Barrons.com